Physician profile
Brian C Miller
NPI 1548403074
$831.68
in general payments reported to CMS, 2019-2025
10 companies · $167 in 2025
The $167 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.42 · 2020: $42.80 · 2021: $99.15 · 2022: $85.77 · 2023: $158 · 2024: $223 · 2025: $167.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $448 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $447.55 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $393.12 | 2019-2025 | Clareon, Centurion, Wavelight Refractive Suite |
| Mallinckrodt Hospital Products INC. | $123.41 | 2023 | Acthar |
| Genmab U.S., INC. | $120.06 | 2024 | Tivdak |
| Tarsus Pharmaceuticals, INC. | $42.32 | 2025 | Xdemvy |
| Allergan, INC. | $38.56 | 2021-2022 | |
| Lensar, INC. | $27.63 | 2022 | |
| Abbott Laboratories | $23.47 | 2022 | |
| Bausch & Lomb Americas INC. | $22.85 | 2024 | Vyzulta |
| Abbvie INC. | $20.38 | 2024 | |
| Eyepoint US, INC. | $19.88 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.